未登录 分享 收藏
Electrocardiographic Right Ventricular Hypertrophy As a Predictor of Mortality in Mitral Transcatheter Edge-to-Edge Repair 心电图右心室肥厚作为经导管二尖瓣边缘对边缘修复术的死亡预测因子 Wangmang, Felix; Richards, Donald; Dhillon, Manvir; Torbati, Tina; Shechter, Alon; Kaewkes, Danon; Patel, Vivek; Koren, Ofir; Skaf, Sabah; Makar, Moody; Chakravarty, Tarun; Makkar, Raj; Mirocha, James; Siegel, Robert; Chonde, Meshe; Chyu, Kuang-Yuh 分享 收藏
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146 仑伐替尼联合帕博利珠单抗在免疫检查点抑制剂治疗后转移性透明细胞肾细胞癌患者中的应用：Study 111/KEYNOTE-146研究的结果 Lee, Chung-Han; Shah, Amishi Yogesh; Rao, Arpit; Taylor, Matthew H.; Di Simone, Christopher; Hsieh, James J.; Pinto, Alvaro; Sarrio, Regina Girones; Cohn, Allen Lee; Bilen, Mehmet Asim; Ribe, Sara Gunnestad; Tennoe, Oyvind Krohn; Richards, Donald; Sweis, Randy F.; Courtright, Jay; Heinrich, Daniel; Perini, Rodolfo; Kubiak, Peter; Bock, Daena; Okpara, Chinyere E. 分享 收藏
Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results 奥潘奈克立定（RGX-202-01）的Ib/II期研究，奥潘奈克立定是一种首创口服型肌酸转运蛋白SLC6A8抑制剂，该研究联合FOLFIRI和贝伐珠单抗（BEV）用于RAS突变（RASmt）二线（2L）晚期/转移性结直肠癌（mCRC）的更新结果 Hendifar, A.; Gong, J.; Spigel, D. R.; Basu-Mallick, A.; Espinosa, A.; Misleh, J. G.; Richards, D.; Boles, J.; Fakih, M.; Paulson, A. S.; Chung, K.; Cohn, A.; Gupta, M.; Johnson, K.; Bechar, N.; Hoffman, K. A.; Spector, S.; Szarek, M.; Wasserman, R.; Rosen, L. S. 分享 收藏
Trastuzumab emtansine in patients (pts) with HER2 mutation-positive (HER2mut) tumors: TAPISTRY study Kim, Jeong Eun; Thomas, David; Gadgeel, Shirish; Corassa, Marcelo; Tan, Tira J.; Girda, Eugenia; Richards, Donald; Tejpar, Sabine; Chen, David; Fang, Junhan; Patel, Sid; Wilson, Timothy R.; Barlesi, Fabrice 分享 收藏
A multicenter, randomized phase 2 study to establish combinations of CBP501, cisplatin and nivolumab for ≥3rd-line treatment of patients with advanced pancreatic adenocarcinoma Enzler, T.; Nguyen, A.; Misleh, J.; Cline, V. J.; Shumway, N.; Johns, M.; Paulson, S.; Siegel, R.; Larsoni, T.; Messersmithj, W.; Richards, D.; Chaves, J.; Pierce, E.; Zalupski, M.; Sahai, V.; Orr, D.; Ruste, S. A.; Haun, A.; Kawabeo, T. 分享 收藏
PATHFINDER 2: A prospective study to evaluate safety and performance of a multi-cancer early detection test in a population setting Giridhar, Karthik V.; Demeure, Michael J.; Kim, Raymond H.; Chen, Justin A.; Gadgeel, Shirish; Kurbegov, Dax; Lopatin, Margarita; Matthews, Roland; Matrana, Marc; McDonnell, Charles; Richards, Donald; Rybicki, Benjamin; Stipec, Gretchen; Nabavizadeh, Nima 分享 收藏
Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+gastroesophageal cancer (GEC) Tehfe, M.; Lee, J.; Rha, S. Y.; Nakamura, Y.; Tabernero, J.; Shitara, K.; Oh, D-Y.; Eads, J.; Marshall, J.; Wainberg, Z. A.; Lee, K-W.; Kang, Y-K.; Liao, C-Y.; Oh, S. Y.; Yeh, K-H.; Richards, D.; Ubowski, M. M.; Zhao, K.; Bhaumik, S.; Strickler, J. H. 分享 收藏
Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for I third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3 Enzler, T.; Nguyen, A.; Misleh, J.; Cline, V. J.; Johns, M. E.; Shumway, N.; Paulson, A. S.; Siegel, R.; Larson, T.; Messersmith, W.; Richards, D.; Chaves, J.; Pierce, E.; Zalupski, M.; Sahai, V.; Orr, D.; Kawabe, T.; Ruste, S. A.; Haun, A. 分享 收藏
Phase Ib/II study of ompenaclid (RGX-202-01), afirst-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC) Hendifar, A.; Spigel, D. R.; Basu-Mallick, A.; Richards, D.; Fakih, M.; Boles, J.; Gupta, M.; Chung, K.; Cohn, A.; Espinosa, A.; Hourdequin, K. C.; Johnson, K.; Michalski, J. M.; Misleh, J. G.; Mukkamala, S.; Paulson, A. S.; Ratnam, S.; Shao, S. H.; Wasserman, R.; Rosen, L. S. 分享 收藏
MRTX-500: Phase II trial of sitravatinib (sitra) plus nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Leal, T. A.; Berz, D.; Rybkin, I.; Iams, W. T.; Bruno, D.; Blakely, C.; Spira, A.; Patel, M.; Waterhouse, D. M.; Richards, D.; Pham, A.; Jotte, R.; Garon, E. B.; Hong, D. S.; Shazer, R.; Yan, X.; Latven, L.; He, K. 分享 收藏
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set 使用独立验证集对基于靶向甲基化的多癌症早期检测测试进行临床验证 Klein, E. A.; Richards, D.; Cohn, A.; Tummala, M.; Lapham, R.; Cosgrove, D.; Chung, G.; Clement, J.; Gao, J.; Hunkapiller, N.; Jamshidi, A.; Kurtzman, K. N.; Seiden, M., V; Swanton, C.; Liu, M. C. 分享 收藏
MRTX-500: Phase II trial of sitravatinib (sitra) plus nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy Leal, T. A.; Berz, D.; Rybkin, I.; Iams, W. T.; Bruno, D.; Blakely, C.; Spira, A.; Patel, M. R.; Waterhouse, D. M.; Richards, D.; Pham, A.; Jotte, R.; Garon, E. B.; Hong, D.; Shazer, R.; Yan, X.; Latven, L.; He, K. 分享 收藏
分享 收藏
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (vol 15, pg 163, 2020) Ramanathan, Ramesh K.; Von Hoff, Daniel D.; Eskens, Ferry; Blumenschein, George, Jr.; Richards, Donald; Genvresse, Isabelle; Reschke, Susanne; Granvil, Camille; Skubala, Adam; Pena, Carol; Mross, Klaus 分享 收藏
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer Ramanathan, Ramesh K.; Von Hoff, Daniel D.; Eskens, Ferry; Blumenschein, George, Jr.; Richards, Donald; Genvresse, Isabelle; Reschke, Susanne; Granvil, Camille; Skubala, Adam; Pena, Carol; Mross, Klaus 分享 收藏
Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer Diamond, Jennifer R.; Becerra, Carlos; Richards, Donald; Mita, Alain; Osborne, Cynthia; O'Shaughnessy, Joyce; Zhang, Chun; Henner, Randall; Kapoun, Ann M.; Xu, Lu; Stagg, Bob; Uttamsingh, Shailaja; Brachmann, Rainer K.; Farooki, Azeez; Mita, Monica 分享 收藏
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma O'Reilly, Eileen M.; Barone, Diletta; Mahalingam, Devalingam; Bekaii-Saab, Tanios; Shao, Spencer H.; Wolf, Julie; Rosano, Molly; Krause, Silva; Richards, Donald A.; Yu, Kenneth H.; Roach, James M.; Flaherty, Keith T.; Ryan, David P. 分享 收藏
Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer Bihani, Teeru; Jung, JungAh; Patel, Hitisha K.; Bardia, Aditya; Kabos, Peter; Kaklamani, Virginia; Jager, Agnes; Aftimos, Philippe; Wilks, Sharon; de Vries, Elisabeth; Harb, Wael; Richards, Donald; Weise, Amy; Wesolowski, Robert; van Oordt, Catharina C. W. Menke-van der Houven; Conkling, Paul; Neven, Patrick; Conlan, Maureen G. 分享 收藏
Final analysis of phase 1 study of elacestrant (RAD1901), a novel selective estrogen receptor degrader (SERD), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer Kaklamani, Virginia; Bardia, Aditya; Wilks, Sharon; Weise, Amy; Richards, Donald; Harb, Wael; Osborne, Cynthia; Wesolowski, Robert; Karuturi, Meghan; Conkling, Paul; Bagley, Rebecca; Jung, JungAh; Bihani, Teeru; Conlan, Maureen; Kabos, Peter 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
.png){kind=icon}
分享.png){kind=icon}
收藏
